Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690, 550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Jan 2017 Long term safety results (n=6194 data cut off 31 Mar 2015) of 2 phase I, 9 phase II, 6 phase III and 2 long term extension studies (NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT00413699, NCT00661661) in adult patients with active Rheumatoid arthritis published in the Annals of the Rheumatic Diseases
- 04 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned End Date changed from 1 Mar 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.